There is a completely different perspective email today from [email protected] about Viraleze being “nasal hygiene” no mention of covid, which parallels the description of Nasodine in its US launch this month. Is the new direction a strategy to launch without seeking FDA approval in the US and compete with Nasodine. Two Australian products with greater efficacy than Paxlovid but great for all respiratory viruses - which have been given terrible treatment in Australia - their country of origin.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-22
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |